Thanks ds for the link. One interesting point arising from the research paper;
Page 1 - Introduction: the point is made that with each of the collaboration agreements signed to date, AstraZeneca, Roche, Pfizer and J&J, that each can yield milestone payments in due course.
The inference appears to be that the collaborations are alive and active [rather than run their course and stalled]. What do we make of the language used in the research paper?
Thanks ds for the link. One interesting point arising from the...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.0¢ | $3.115M | 15.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 837577 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 343176 | 2 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |